Rinsho Shinkeigaku (Clinical Neurology)

The 51st Annual Meeting of the Japanese Society of Neurology

Branch atheromatous disease: How do we analyze its pathophysiology and treat to prevent the progression of neurological symptoms for good prognosis?

Hidetaka Takeda, M.D.1), Makoto Takagi, M.D.2), Yasumasa Yamamoto, M.D.3) and J-BAD Investigators4)

1)Department of Neurology and Cerebrovascular Medicine, Saitama International Medical Center, Saitama Medical University
2)Department of Neurology, Saiseikai Central Hospital
3)Department of Neurology, Kyoto Second Red Cross Hospital
4)J-BAD Registry

Branch atheromatous disease (BAD) has been recognized as one of the types of stroke which is often associated with clinical deterioration. Coagulation and platelet activation should play an important role in early neurological progression of BAD, which include complicated aspects for understanding the pathophysiology and the treatment. It has been suggested that multidrug combination therapy involving antiplatelet and anticoagulation could not prevent worsening of symptoms in the acute stage of BAD: nevertheless it should be important to improve prognosis of patients in the chronic stage. Further investigation including randomized controlled study will be needed for the accumulation of various evidences.
Full Text of this Article in Japanese PDF (381K)

(CLINICA NEUROL, 50: 921|924, 2010)
key words: branch atheromatous disease (BAD), microatheroma, multidrug combination therapy, white matter lesion

(Received: 22-May-10)